Strong quarter puts Abilify on track for record US year
This article was originally published in Scrip
Executive Summary
Otsuka's blockbuster atypical antipsychotic Abilify (aripiprazole) has posted its strongest quarterly growth so far this year in the US and looks set to achieve its highest ever sales in this market in 2013, helped by new formulations and indications.